- Home
- CAN vs ITOS Comparison
CAN vs ITOS Comparison
Compare CAN & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- ITOS
- Stock Information
- Founded
- CAN 2013
- ITOS 2011
- Country
- CAN Singapore
- ITOS United States
- Employees
- CAN N/A
- ITOS N/A
- Industry
- CAN Semiconductors
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAN Technology
- ITOS Health Care
- Exchange
- CAN Nasdaq
- ITOS Nasdaq
- Market Cap
- CAN 384.3M
- ITOS 381.2M
- IPO Year
- CAN 2019
- ITOS 2020
- Fundamental
- Price
- CAN $0.70
- ITOS $10.18
- Analyst Decision
- CAN Strong Buy
- ITOS Hold
- Analyst Count
- CAN 6
- ITOS 6
- Target Price
- CAN $2.67
- ITOS $10.60
- AVG Volume (30 Days)
- CAN 28.9M
- ITOS 911.6K
- Earning Date
- CAN 08-14-2025
- ITOS 08-07-2025
- Dividend Yield
- CAN N/A
- ITOS N/A
- EPS Growth
- CAN N/A
- ITOS N/A
- EPS
- CAN N/A
- ITOS N/A
- Revenue
- CAN $317,009,000.00
- ITOS $35,000,000.00
- Revenue This Year
- CAN $160.28
- ITOS N/A
- Revenue Next Year
- CAN $35.68
- ITOS N/A
- P/E Ratio
- CAN N/A
- ITOS N/A
- Revenue Growth
- CAN 65.68
- ITOS 177.89
- 52 Week Low
- CAN $0.53
- ITOS $4.80
- 52 Week High
- CAN $3.27
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- CAN 53.84
- ITOS 67.57
- Support Level
- CAN $0.58
- ITOS $9.95
- Resistance Level
- CAN $0.62
- ITOS $10.20
- Average True Range (ATR)
- CAN 0.05
- ITOS 0.15
- MACD
- CAN 0.01
- ITOS -0.09
- Stochastic Oscillator
- CAN 75.53
- ITOS 90.00
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.